Berghöfer A, Kossmann B, Müller-Oerlinghausen B
Department of Psychiatry, Freie Universität Berlin, Germany.
Acta Psychiatr Scand. 1996 May;93(5):349-54. doi: 10.1111/j.1600-0447.1996.tb10659.x.
We analysed the recurrences of 86 patients with monopolar and bipolar mood and schizoaffective disorders treated with lithium over a period of 8.2 years on average in a specialized out-patient clinic. Lithium medication was discontinued by 24% of patients. Diagnosis, age and gender had no influence on the mean morbidity index. Bipolar and schizoaffective patients suffered from more severe recurrences, resulting in hospital admissions, than monopolar patients. A significant decrease in intensity of manic episodes and a significant shortening of depressive episodes was observed over a 10-year treatment period. However, the percentage of manic episodes among all episodes remained constant. There was no indication of a loss of the prophylactic effect in a subgroup of 30 patients who had been treated for a minimum of 10 years. The morbidity index also remained constant over 10 years in the whole sample. Furthermore, the mean lithium blood levels as well as the additional medication in this subgroup could be lowered in the second half of the treatment decade as compared to the initial 5 years.
我们分析了在一家专业门诊平均接受8.2年锂盐治疗的86例单相和双相情感障碍及分裂情感性障碍患者的复发情况。24%的患者停用了锂盐药物。诊断、年龄和性别对平均发病指数没有影响。与单相情感障碍患者相比,双相情感障碍和分裂情感性障碍患者的复发更为严重,导致住院治疗。在10年的治疗期内,躁狂发作强度显著降低,抑郁发作时间显著缩短。然而,所有发作中躁狂发作的百分比保持不变。在接受至少10年治疗的30例患者亚组中,没有迹象表明预防效果丧失。在整个样本中,发病指数在10年内也保持不变。此外,与最初的5年相比,在治疗十年的后半期,该亚组的平均血锂水平以及额外用药量都可以降低。